Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2022

View Archived Issues

CHIN-117 reduces inflammation in murine model of colitis

Researchers highlight use of NUAK2 inhibitor HTH-02-006 for treating prostate cancer

Eternity Bioscience patents new Raf kinase inhibitors

Athira Pharma discloses new HGFR modulators

Engineered CAR NK cells can be an effective therapy against SARS-CoV-2 infection

Lengo Therapeutics presents new EGFR and HER2 inhibitors

New NFE2L2 activators identified by Sitryx Therapeutics

Arena Pharmaceuticals synthesizes new 5-HT2A receptor antagonists

SA-FasL microgels induce immune acceptance of islet transplantation

Chemokine-targeting B7-H3.CAR-T cells show enhanced activity against NSCLC brain tumor lesions

Aging mice brains have slower protein turnover, linking aging to neurodegenerative disease

FDA awards orphan drug designation to TTI-101 for IPF

NHLBI grant supports IND-enabling studies of NMX-1 for triple-negative breast cancer

IMT-504 ameliorates neuropathic pain by modulating neuroimmune milieu

VeriSIM Life partners with Total Brain to support neurological drug development

Discovery of novel microtubule targeting agent for the treatment of cancer

Forma Therapeutics introduces USP1 inhibitor FT-3171

New myasthenia gravis rat model developed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal
BioWorld
The already-thriving CAR T space took another big stride forward as Eli Lilly and Co. disclosed its plan to acquire Boston-based Kelonia Therapeutics Inc. for as...